Castle Biosciences Inc
NASDAQ:CSTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (6.4), the stock would be worth $23.51 (1% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.4 | $23.69 |
0%
|
| 3-Year Average | 6.4 | $23.51 |
-1%
|
| Industry Average | 18.7 | $68.82 |
+191%
|
| Country Average | 16.7 | $61.47 |
+159%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
703.3m USD | 6.4 | -29.1 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14 | 55.7 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 10.7 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 11.1 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.9B EUR | 12.3 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 14.5 | 21.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 16 | 24.8 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 6.5 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -64.9 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 10.4 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
